SALK NEWS

Salk Institute for Biological Studies - SALK NEWS

Salk News


Salk Institute empowers future scientists with Prebys Foundation support

LA JOLLA—The Salk Institute will receive a generous gift from the Prebys Foundation as part of a rapid-response funding initiative to safeguard San Diego’s biomedical research ecosystem. This funding will support three years of Salk’s five cornerstone education pipeline and training programs: the Heithoff-Brody High School Summer Scholars, Summer Undergraduate Research Fellowship (SURF), Salk Edge Program, Discover Symposium, and Rising Stars Symposium.


Cannabis pangenome reveals potential for medicinal and industrial use

LA JOLLA—Cannabis has been a globally important crop for millennia. While best known today as marijuana for its psychoactive cannabinoid THC (tetrahydrocannabinol), historically, cannabis has been a cornerstone of human civilization, providing seed oil, textiles, and food for more than 10,000 years. Today, cannabis remains an understudied and underutilized resource, but United States legislation passed in 2014 and 2018 have re-energized cannabis crop development for medicinal, grain, and fiber applications.


Action! Proteins critical to healthy brain development captured on film

LA JOLLA—Our cells rely on microscopic highways and specialized protein vehicles to move everything—from positioning organelles to carting protein instructions to disposing of cellular garbage. These highways (called microtubules) and vehicles (called motor proteins) are indispensable to cellular function and survival.


Stephen Quake and David Julius named Salk Institute Nonresident Fellows

LA JOLLA—The Salk Institute welcomes two new Nonresident Fellows, UC San Francisco Professor David Julius and Stanford Professor Stephen Quake. The two scientists join a group of eminent scientific advisors who guide Salk’s leadership.


Terrence Sejnowski elected to the Royal Society and the American Philosophical Society

LA JOLLA—Salk Professor Terrence Sejnowski, head of the Computational Neurobiology Laboratory and holder of the Francis Crick Chair, has been elected to the Royal Society and the American Philosophical Society. These prestigious elections recognize his outstanding leadership and extraordinary achievement in computational neuroscience.


Salk Institute welcomes financial manager Horacio Valeiras to Board of Trustees

LA JOLLA—Horacio Valeiras, CEO of Frontier Global Partners, has been newly appointed to the Salk Institute’s Board of Trustees. He will work alongside business and nonprofit leaders from around the world, all committed to supporting Salk’s innovative, high-quality scientific research.


Estrogen-related receptors could be key to treating metabolic and muscular disorders

LA JOLLA—A new Salk Institute study suggests estrogen-related receptors could be a key to repairing energy metabolism and muscle fatigue.


Salk Institute scientists named semifinalists in XPRIZE Healthspan competition

LA JOLLA—Salk Institute Professor Satchidananda Panda has been named a semifinalist in the XPRIZE Healthspan competition. Panda’s team is known for its expertise in circadian rhythms, the body’s internal timetable that determines the timing of our behaviors, such as sleep and wakefulness, and almost every bodily function.


Salk Institute Professor Emeritus Greg Lemke elected to National Academy of Sciences

LA JOLLA— The National Academy of Sciences recently announced that Salk Institute Professor Emeritus Greg Lemke is one of 120 new members and 30 foreign associates to be elected to the academy in recognition of their distinguished and continuing achievements in original research. This election is considered one of the highest honors accorded to a scientist in the United States. Lemke, a neuroscientist, is known for discovering the TAM family of cell receptors and their role in brain inflammation. His recognition brings the number of Salk faculty elected to the National Academy of Sciences to 14.


Salk Institute promotes three faculty members in neuroscience, immunology, and cancer research

LA JOLLA—Three Salk Institute faculty members have been promoted for their notable, innovative contributions to science. Associate Professors Nicola Allen and Diana Hargreaves were promoted to full professors, and Assistant Professor Jesse Dixon was promoted to associate professor. The promotions were based on Salk faculty and nonresident fellow recommendations and approved by Salk’s president and Board of Trustees on April 4, 2025.


Peptide imitation is the sincerest form of plant flattery

LA JOLLA—Industrial farming practices often deplete the soil of important nutrients and minerals, leaving farmers to rely on artificial fertilizers to support plant growth. In fact, fertilizer use has more than quadrupled since the 1960s, but this comes with serious consequences. Fertilizer production consumes massive amounts of energy, and its use pollutes the water, air, and land.


The day polio met its match: Celebrating 70 years of the Salk vaccine

Seventy years ago, on April 12, 1955, a scientific breakthrough changed the course of public health and inspired hope worldwide. The polio vaccine developed by Jonas Salk and colleagues was officially declared “safe, effective, and potent”—a moment heralded as a triumph of medicine over one of the most feared diseases of the 20th century.


Salk Institute receives $4.5 million gift from Trustee Richard A. Heyman to enable early-stage innovative research

LA JOLLA—Richard A. Heyman, a member of the Salk Institute’s Board of Trustees, and his wife, Anne Daigle, have donated $4.5 million to establish the new Richard A. Heyman Collaborative Innovation Fund to support Institute faculty on collaborative, early-stage studies aimed at big, bold questions.


Salk Institute appoints Michelle Chamberlain as Vice President of External Relations

LA JOLLA—The Salk Institute has named Michelle Chamberlain as Vice President of External Relations. She will assume the role on April 2, 2025.


New study explains how antidepressants can protect against infections and sepsis

LA JOLLA—Antidepressants like Prozac are commonly prescribed to treat mental health disorders, but new research suggests they could also protect against serious infections and life-threatening sepsis. Scientists at the Salk Institute have now uncovered how the drugs are able to regulate the immune system and defend against infectious disease—insights that could lead to a new generation of life-saving treatments and enhance global preparedness for future pandemics.


Celebrating 50 years of discovery: Professor Tony Hunter’s half-century legacy at the Salk Institute

LA JOLLA—The Salk Institute is proud to celebrate Professor Tony Hunter’s 50 years as a cancer biology pioneer whose fundamental discoveries have inspired the development of more than 80 cancer drugs. Since joining the Institute’s faculty in February 1975, Hunter has been a cornerstone of the Salk community, contributing to transformational discoveries and mentoring more than 100 trainees, many of whom have also become scientific leaders.


Boosting this molecule could help retain muscle while losing fat

LA JOLLA—About one in eight adults in the United States has tried or currently uses a GLP-1 medication, and a quarter of those users cite weight loss as their main goal. But weight loss doesn’t discriminate between fat and muscle. Patients using GLP-1 drugs can experience rapid and substantial muscle loss, accounting for as much as 40% of their total weight loss. So how can we lose weight without also losing critical muscle?


Salk Institute welcomes technology leader Fred Luddy to Board of Trustees

LA JOLLA—The Salk Institute today announced the appointment of Fred Luddy, founder of ServiceNow, to its Board of Trustees.


Salk Institute names plant geneticist Detlef Weigel as Nonresident Fellow

LA JOLLA—The Salk Institute has named plant geneticist Detlef Weigel a Nonresident Fellow, making him a member of the group of eminent scientific advisors who guide the Institute’s leadership. Weigel is a director and scientific member at the Max Planck Institute for Biology Tübingen in Germany, as well as an adjunct professor at the Salk Institute and University of Tübingen.


Bile acids exacerbate liver cancer, dietary supplement may offer relief

LA JOLLA—Immunotherapy is a modern approach to cancer treatment that uses a patient’s own immune system to help fight tumors. It has made an incredible impact on treating cancers in many different organ systems, including the lung, kidney, and bladder—but for other cancers, such as liver cancer, the therapy has been much less effective. This discrepancy is especially concerning as liver cancer rates have nearly tripled in the last 40 years.